HVO Hvivo Plc

TIDMORPH

RNS Number : 3915C

Open Orphan PLC

07 February 2020

7 February 2020

Open Orphan plc

("Open Orphan" or the "Company")

Significant shareholder

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, has been advised today that, as of 31 January 2020, Jupiter Asset Management Limited's ("Jupiter") interest in the Ordinary Shares of 0.1p in the Company fell below 3% of the total voting rights of the Company. Accordingly, Jupiter have ceased to be a significant shareholder in the Company, as defined by the AIM Rules for Companies.

For further information please contact:

 
                                                     +353 (0)1 644 
 Open Orphan plc                                      0007 
  Cathal Friel, Executive Chairman                    +44 (0)20 7347 
  Trevor Phillips, Chief Executive Officer            5350 
 
 Arden Partners plc (Nominated Adviser and Joint 
  Broker)                                           +44 (0)20 7614 
  John Llewellyn-Lloyd / Benjamin Cryer              5900 
 
 
 Davy (Euronext Growth Adviser and Joint Broker)    +353 (0)1 679 
  Anthony Farrell                                    6363 
 
 
 Camarco (Financial PR) 
                                                    +44 (0)20 3757 
 Tom Huddart / Daniel Sherwen                        4980 
 

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Corona virus in 2020 The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUPUUCPUPUGAM

(END) Dow Jones Newswires

February 07, 2020 10:42 ET (15:42 GMT)

Grafico Azioni Hvivo (LSE:HVO)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Hvivo (LSE:HVO)
Storico
Da Apr 2023 a Apr 2024